Re: "Cancer mortality among us men and women with asthma and hay fever" [2]

American Journal of Epidemiology

Volumn 163, Issue 4, 2006, Pages 394-395

  Schabath, Matthew B ^a   Gorlova, Olga Y ^a   Spitz, Margaret R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; NON PRESCRIPTION DRUG;

CANCER;

ALLERGY; ASTHMA; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CONFIDENCE INTERVAL; ECZEMA; EMPHYSEMA; GENETIC VARIABILITY; HAY FEVER; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LETTER; LUNG CANCER; PRESCRIPTION; STATISTICAL SIGNIFICANCE;

ASTHMA; FEMALE; HUMANS; MALE; NEOPLASMS; RHINITIS, ALLERGIC, SEASONAL; RISK ASSESSMENT;

EID: 32544459284     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwj065     Document Type: Letter

References (5)

1. Turner MC, Chen Y, Krewski D, et al. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005;162:212-21.
2. Castaing M, Youngson J, Zaridze D, et al. Is the risk of lung cancer reduced among eczema patients? Am J Epidemiol 2005;162:542-7.
3. Schabath MB, Delclos GL, Martynowicz MM, et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 2005;161:412-22.
4. Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer. Advance Access: October 10, 2005. (DOI: 10.1002/ijc.21561).
5. Report of the Lung Cancer Progress Review Group. Progress Review Groups (PRGS), Office of Science Planning and Assessment (OSPA), National Cancer Institute, 2001. (http://prg. nci.nih.gov/lung/finalreport.html).